Human papillomavirus and cervical cancer: Burden of illness and basis for prevention

American Journal of Managed Care

Volumn 12, Issue SUPPL. 17, 2006, Pages

  Trottier, Helen ^b   Franco, Eduardo L ^a  

^a MCGILL UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ANUS CANCER; ARTICLE; CANCER CYTODIAGNOSIS; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CONDYLOMA; CONDYLOMA ACUMINATUM; DEVELOPED COUNTRY; DEVELOPING COUNTRY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 6; INFECTION PREVENTION; INFECTION RISK; MORBIDITY; MOUTH CARCINOMA; PAPANICOLAOU TEST; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS CARCINOGENESIS; VIRUS TRANSMISSION; WART VIRUS;

COST OF ILLNESS; FEMALE; HUMANS; MALE; PAPILLOMAVIRIDAE; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 33845994430     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (97)

1. Ebrahim SH, McKenna MT, Marks JS. Sexual behaviour: related adverse health burden in the United States. Sex Transm Infect. 2005;81:38-40.
2. IARC. Epidemiology of infection: human papillomaviruses. Carcinog Risk Chem Hum. 1995;64:60-65.
3. Franco EL, Villa LL, Richardson H, Rohan T, Ferenczy A. Epidemiology of cervical human papillomavirus infection. In: Franco E, Monsonego J, eds. New Developments in Cervical Cancer Screening and Prevention. Oxford, UK: Blackwell Science; 1997:14-22.
4. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005;32(suppl 1):S16-S24.
5. Bosch FX, de Sanjose S. Chapter 1: human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;(31):3-13.
6. Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev. 2003;12:485-490.
7. Herrero R, Castle PE, Schiffman M, et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis. 2005;191:1796-1807.
8. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88:63-73.
9. Burchell AN, Winer RL, de Sanjose S, Franco EL. Chapter 6: epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006;24(suppl 3):S52-S61.
10. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis. 1994;169:235-240.
11. Liaw KL, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis. 2001;183:8-15.
12. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24(suppl 1):S1-S15.
13. Kjaer SK, Chackerian B, van den Brule AJ, et al. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev. 2001;10:101-106.
14. Rylander E, Ruusuvaara L, Almstromer MW, Evander M, Wadell G. The absence of vaginal human papillomavirus 16 DNA in women who have not experienced sexual intercourse. Obstet Gynecol. 1994;83:735-737.
15. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423-428.
16. Franco EL, Rohan TE, Villa LL. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst. 1999;91:506-511.
17. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001;357:1831-1836.
18. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157:218-226.
19. Syrjanen S, Shabalova I, Petrovichev N, et al. Age-specific incidence and clearance of high-risk human papillomavirus infections in women in the former Soviet Union. Int J STD AIDS. 2005;16:217-223.
20. Giuliano AR, Papenfuss M, Abrahamsen M, Inserra P. Differences in factors associated with oncogenic and nononcogenic human papillomavirus infection at the United States-Mexico border. Cancer Epidemiol Biomarkers Prev. 2002;11:930-934.
21. Trottier H, Mahmud S, Costa MC, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2006;15:1274-1280.
22. Cates W Jr. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex Transm Dis. 1999;26(4 suppl):S2-S7.
23. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev. 1988;10:122-163.
24. Schiffman M, Castle PE. Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med. 2003;127:930-934.
25. Schiffman M, Kjaer SK. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr. 2003;(31):14-19.
26. Marrazzo JM, Koutsky LA, Kiviat NB, Kuypers JM, Stine K. Papanicolaou test screening and prevalence of genital human papillomavirus among women who have sex with women. Am J Public Health. 2001;91:947-952.
27. Castellsague X, Bosch FX, Munoz N. The male role in cervical cancer. Salud Publica Mex. 2003;45(suppl 3):S345-S353.
28. Burchell AN, Richardson H, Mahmud SM, et al. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol. 2006;163:534-543.
29. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis. 2002;29:725-735.
30. Edwards S, Carne C. Oral sex and the transmission of viral STIs. Sex Transm Infect. 1998;74:6-10.
31. Sonnex C, Strauss S, Gray JJ. Detection of human papillomavirus DNA on the fingers of patients with genital warts. Sex Transm Infect. 1999;75:317-319.
32. Gervaz P, Allal AS, Villiger P, Buhler L, Morel P. Squamous cell carcinoma of the anus: another sexually transmitted disease. Swiss Med Wkly. 2003;133:353-359.
33. Armstrong LR, Preston EJ, Reichert M, et al. Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin Infect Dis. 2000;31:107-109.
34. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997;102:3-8.
35. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001;285:2995-3002.
36. Sellors JW, Karwalajtys TL, Kaczorowski J, et al. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ. 2003;168:421-425.
37. Rousseau MC, Franco EL, Villa LL, et al. A cumulative case-control study of risk factor profiles for oncogenic and nononcogenic cervical human papillomavirus infections. Cancer Epidemiol Biomarkers Prev. 2000;9:469-476.
38. Aral SO, Holmes KK. Social and behavioural determinants of epidemiology of STDs: industrialized and developing countries. In: Holmes KK, Mardh P, Sparling PF, et al, eds. Sexually Transmitted Diseases. 3rd ed. New York, NY: McGraw-Hill; 1999:39-76.
39. Kahn JA, Rosenthal SL, Succop PA, Ho GY, Burk RD. Mediators of the association between age of first sexual intercourse and subsequent human papillomavirus infection. Pediatrics. 2002;109:E5.
40. Stone KM, Timyan J, Thomas EL. Barrier methods for the prevention of sexually transmitted diseases. In: Holmes KK, Mardh P, Sparling PF, et al, eds. Sexually Transmitted Diseases. 3rd ed. New York, NY: McGraw-Hill; 1999:1307-1321.
41. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006;354:2645-2654.
42. Wang SS, Hildesheim A. Chapter 5: viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr. 2003;(31):35-40.
43. Maciag PC, Schlecht NF, Souza PS, Rohan TE, Franco EL, Villa LL. Polymorphisms of the human leukocyte antigen DRB1 and DQB1 genes and the natural history of human papillomavirus infection. J Infect Dis. 2002;186:164-172.
44. Garcia-Closas R, Castellsague X, Bosch X, Gonzalez CA. The role of diet and nutrition in cervical carcinogenesis: a review of recent evidence. Int J Cancer. 2005;117:629-637.
45. Giuliano AR, Siegel EM, Roe DJ, et al. Dietary intake and risk of persistent human papillomavirus (HPV) infection: the Ludwig-McGill HPV Natural History study. J Infect Dis. 2003;188:1508-1516.
46. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine. 2006;24:5571-5583.
47. Schlecht NF, Trevisan A, Duarte-Franco E, et al. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer. 2003;103:519-524.
48. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004;324:17-27.
49. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527.
50. IARC Working Group. Human papillomaviruses. IARC Monographs on the evaluation of carcinogenic risks to humans. Vol. 64, International Agency for Research on Cancer, Lyon, 1995.
51. Schiffman MH, Brinton LA. The epidemiology of cervical carcinogenesis. Cancer. 1995;76(10 suppl):1888-1901.
52. Herrero R. Epidemiology of cervical cancer. J Natl Cancer Inst Monogr. 1996;21:1-6.
53. Holly EA. Cervical intraepithelial neoplasia, cervical cancer, and HPV. Annu Rev Public Health. 1996;17:69-84.
54. Walboomers JM, Meijer CJ. Do HPV-negative cervical carcinomas exist? J Pathol. 1997;181:253-254.
55. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
56. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 1993;85:958-964.
57. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87:796-802.
58. WHO Vaccine Report. The current status of development of prophylactic vaccines against human papillomavirus infection. Report of a technical meeting. World Health Organization; 1999. Available at: http://www.who. int/vaccine_research/documents/en/hpv1.pdf. Accessed October 20, 2006.
59. zur Hausen H. Papillomavirus infections-a major cause of human cancers. Biochim Biophys Acta. 1996;1288:F55-F78.
60. Spence A, Franco E, Ferenczy A. The role of human papillomaviruses in cancer: evidence to date. Am J Cancer. 2005;4:49-64.
61. Strauss MJ, Khanna V, Koenig JD, et al. The cost of treating genital warts. Int J Dermatol. 1996;35:340-348.
62. Koshiol JE, Laurent SA, Pimenta JM. Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis. 2004;31:748-752.
63. Alam M, Stiller M. Direct medical costs for surgical and medical treatment of condylomata acuminata. Arch Dermatol. 2001;137:337-341.
64. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide [database]. Lyon, France: International Agency for Research on Cancer (IARC); CancerBase No. 5, version 2.0; 2004.
65. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999;83:18-29.
66. National Cancer Institute Surveillance Epidemiology and End Results (SEER). SEER Cancer Statistics Review, 1975-2003. Available at: http://www.seer.cancer. gov/csr/1975_2003. Accessed December 7, 2006.
67. Platz CE, Benda JA. Female genital tract cancer. Cancer. 1995;75(1 suppl):270-294.
68. Franco EL, Ferenczy A. Part III, site-specific precancerous conditions: cervix. In: Franco EL, Rohan TE, eds. Cancer Precursors: Epidemiology, Detection, and Prevention. New York, NY: Springer-Verlag; 2002:249-286.
69. Thomas KK, Hughes JP, Kuypers JM, Kiviat NB, Lee SK, Adam DE, Koutsky LA. Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis. 2000;182:1097-1102.
70. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet. 1999;354:20-25.
71. Ylitalo N, Josefsson A, Melbye M, et al. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res. 2000;60:6027-6032.
72. Ostor AG. National history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12:186-192.
73. Manos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA. 1999;281:1605-1610.
74. Miller AB, Nazeer S, Fonn S, et al. Report on consensus conference on cervical cancer screening and management. Int J Cancer. 2000;86:440-447.
75. Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC. Report on a Workshop of the UICC Project on Evaluation of Screening for Cancer. Int J Cancer. 1990;46:761-769.
76. Wright TC, Cox JT, Massad LS, Wiggs, LB, Wilkinson EJ, for the 2001 ASCCP-sponsored consensus conference. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287:2120-2129.
77. Franco EL, Mayrand MH, Trottier H. Cervical cancer prevention. Promises and perils in a changing landscape. Oncol Exchange. 2006;5:9-13,40.
78. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA. 1994;271:1866-1899.
79. Insinga RP, Glass AG, Rush BB. Pap screening in a U.S. health plan. Cancer Epidemiol Biomarkers Prev. 2004;13:355-360.
80. Lawson HW, Lee NC, Thames SF, Henson R, Miller DS. Cervical cancer screening among low-income women: results of a national screening program, 1991-1995. Obstet Gynecol. 1998;92:745-752.
81. Centers for Disease Control and Prevention (CDC). Results from the National Breast and Cervical Cancer Early Detection Program, October 31, 1991-September 30, 1993. MMWR. 1994;43:530-534.
82. Janerich DT, Hadjimichael O, Schwartz PE, et al. The screening histories of women with invasive cervical cancer, Connecticut. Am J Public Health. 1995;85:791-794.
83. Sung HY, Kearney KA, Miller M, Kinney W, Sawaya GF, Hiatt RA. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer. 2000;88:2283-2289.
84. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol. 2004;191:114-120.
85. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757-1765.
86. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet. 2006;367:1247-1255.
87. Nanda K, McCroory DC, Myers ER et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132:810-819.
88. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smear: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst. 2004;96:250-251.
89. Franco EL. Chapter 13: primary screening of cervical cancer with human papillomavirus tests. J Natl Cancer Inst Monogr. 2003;31:89-96.
90. Franceschi S. The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer. Recent Results Cancer Res. 2005;166:277-297.
91. Cuzick J, Mayrand MH, Ronco G, Snijders P, Wardle J. Chapter 10: new dimensions in cervical cancer screening. Vaccine. 2006;24(suppl 3):S90-S97.
92. Ronco G, Segnan N, Giorgi-Rossi P, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst. 2006;98:765-774.
93. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003;362:1871-1876.
94. Elfgren K, Rylander E, Radberg T, et al. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol. 2005;193:650-657.
95. Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M. Routine screening with primary HPV testing and cytology triage protocol in a randomised setting. Int J Cancer. 2005;93:862-867.
96. Bulkmans NW, Rozendaal L, Snijders PJ, et al. POBASCAM, a population-based randomised controlled trial for implementation of high-risk HPV testing in cervical screening. Int J Cancer. 2004;110:94-110.
97. Mayrand MH, Duarte-Franco E, Coutlee F, et al. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer. 2006;119:615-623.